for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Bellerophon Therapeutics Inc

BLPH.OQ

Latest Trade

0.59USD

Change

0.01(+1.30%)

Volume

30,777

Today's Range

0.56

 - 

0.59

52 Week Range

0.49

 - 

1.25

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
0.58
Open
0.58
Volume
30,777
3M AVG Volume
2.87
Today's High
0.59
Today's Low
0.56
52 Week High
1.25
52 Week Low
0.49
Shares Out (MIL)
68.91
Market Cap (MIL)
40.73
Forward P/E
-2.57
Dividend (Yield %)
--

Next Event

Q3 2019 Bellerophon Therapeutics Inc Earnings Release

Latest Developments

More

Bellerophon Reports Q2 Loss Per Share $0.06

Bellerophon Says FDA Agreed With Proposed Primary Endpoint

Bellerophon To Present Additional Data From Cohort 1 Of Ongoing Phase 2/3 Study Of Inopulse For Treatment Of Pulmonary Hypertension Associated With Interstitial Lung Disease

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Bellerophon Therapeutics Inc

Bellerophon Therapeutics, Inc. is a clinical-stage therapeutics company. The Company is focused on developing products at the intersection of drugs and devices that address medical needs in the treatment of cardiopulmonary diseases. The Company is focused on the development of its nitric oxide therapy for patients with pulmonary hypertension (PH), using its delivery system, INOpulse, with pulmonary arterial hypertension (PAH) as the lead indication. Its INOpulse device has a mechanism that delivers brief, targeted pulses of nitric oxide timed to occur at the beginning of a breath for delivery to the alveoli of the lungs, which minimizes the amount of drug required for treatment. The Company's second program, BCM, is a medical device focused to prevent congestive heart failure following a ST Segment Elevation Myocardial Infarction (STEMI), which is a type of severe heart attack. The Company's BCM is in PRESERVATION I clinical trial.

Industry

Biotechnology & Drugs

Contact Info

184 Liberty Corner Rd Ste 302

+1.908.5744770

http://www.bellerophon.com/

Executive Leadership

Jonathan M. Peacock

Chairman of the Board, President

Fabian Tenenbaum

Chief Executive Officer, Chief Financial Officer, Chief Business Officer, Director

Assaf Korner

Chief Financial Officer

Martin D. Meglasson

Chief Scientific Officer, Vice President

Reinilde Heyrman

Vice President, Chief Clinical Development Officer and Secretary

Key Stats

2.00 mean rating - 2 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-1.570

2018

0.050

2019(E)

-0.227
Price To Earnings (TTM)
7.06
Price To Sales (TTM)
--
Price To Book (MRQ)
3.55
Price To Cash Flow (TTM)
7.21
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
30.53
Return on Equity (TTM)
20.99

Latest News

BRIEF-Bellerophon Therapeutics Q1 Shr Loss $0.04

* BELLEROPHON PROVIDES BUSINESS UPDATE AND REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

BRIEF-Bellerophon Reaches Agreement With FDA On Study Design Of Phase 2b Trial Of INOpulse

* BELLEROPHON REACHES AGREEMENT WITH FDA ON STUDY DESIGN OF PHASE 2B TRIAL OF INOPULSE® FOR TREATMENT OF PULMONARY HYPERTENSION ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE

BRIEF-Bellerophon Q4 Loss Per Share $0.44

* BELLEROPHON PROVIDES BUSINESS UPDATE AND REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS

BRIEF-Bellerophon Says Over 100 Patients In Late-Stage Study Testing Inopulse For Treatment Of High Blood Pressure

* BELLEROPHON THERAPEUTICS ANNOUNCES ENROLLMENT EXCEEDS 100 PATIENTS IN PHASE 3 INOVATION-1 STUDY EVALUATING INOPULSE® FOR TREATMENT OF PULMONARY ARTERIAL HYPERTENSION

BRIEF-Bellerophon Says First Patient Enrolled In Phase 2B Study Evaluating Inopulse For Treating Pulmonary Hypertension

* BELLEROPHON-FIRST PATIENT ENROLLED IN PHASE 2B STUDY EVALUATING INOPULSE FOR TREATING PULMONARY HYPERTENSION ASSOCIATED WITH INTERSTITIAL LUNG DISEASE

BRIEF-Bellerophon Appoints Ted Wang To Its Board Of Directors

* BELLEROPHON APPOINTS TED WANG, PH.D., OF PUISSANCE CAPITAL MANAGEMENT, TO ITS BOARD OF DIRECTORS

BRIEF-Bellerophon Therapeutics reports Q3 loss per share $0.22

* Bellerophon provides business update and reports third quarter 2017 financial results

BRIEF-Bellerophon Therapeutics says selling stockholders may offer, resell up to 38.9 mln shares - SEC filing

* Bellerophon Therapeutics Inc files to say selling stockholders may offer and resell up to 38.9 million shares of co's common stock - SEC filing

BRIEF-Bellerophon announces $23 million private placement

* Bellerophon Therapeutics Inc - financing was led by Puissance Capital Management and Venrock Healthcare Capital Partners

BRIEF-Bellerophon announces positive top line Phase 2 data of INOpulse

* Bellerophon announces positive top line Phase 2 data of INOpulse for treatment of Pulmonary Hypertension associated with Chronic Obstructive Pulmonary Disease

BRIEF-Bellerophon reports Q2 loss per share $0.12

* Bellerophon reports second quarter 2017 financial results and provides business update

BRIEF-Bellerophon announces FDA agreement on phase 2B study design for Inopulse

* Bellerophon announces FDA agreement on phase 2B study design for Inopulse in pulmonary hypertension associated with interstitial lung disease (PH-ILD)

BRIEF-CVI Investments reports 5.7 percent passive stake in Bellerophon Therapeutics as of May 10

* CVI Investments Inc reports 5.7 percent passive stake in Bellerophon Therapeutics Inc as of May 10, 2017 - SEC filing Source text : [ID:http://bit.ly/2pPdxAg] Further company coverage:

BRIEF-Bellerophon to issue 2 mln registered shares of common stock

* Bellerophon announces $3.0 million registered direct offering

BRIEF-Bellerophon Therapeutics says co terminated sales agreement - sec filing

* Bellerophon Therapeutics says effective April 26 , co terminated at market issuance sales agreement entered into on May 27, 2016 - SEC Filing

BRIEF-Bellerophon Therapeutics announces new data from phase 2 study

* Bellerophon therapeutics - announced new data from phase 2 study evaluating use of inopulse in idiopathic pulmonary fibrosis patients with pulmonary hypertension

BRIEF-Bellerophon Therapeutics board appointed Megan Schoeps as principal financial officer

* On March 10, 2017, board appointed Megan Schoeps as principal financial officer of company Source text for Eikon: Further company coverage:

BRIEF-Bellerophon Therapeutics reports Q4 loss per share of $0.37

* Bellerophon reports fourth quarter 2016 financial results and provides business update

BRIEF-Bellerophon Therapeutics announces $12 mln public offering

* Bellerophon Therapeutics Inc - offering was priced at $0.70 per class a unit

BRIEF-Bellerophon Therapeutics entered into a new employment agreement with Fabian Tenenbaum on Nov 10

* On nov 10, co entered into a new employment agreement with fabian tenenbaum, its cfo to serve as company's ceo

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up